BACKGROUND: Large clinical trials have demonstrated the therapeutic efficacy of oseltamivir against influenza. We assessed the indirect effectiveness of oseltamivir in reducing secondary household transmission in an incident cohort of influenza index patients and their household members. METHODS: We recruited index outpatients whose rapid test results were positive for influenza from February through September 2007 and January through September 2008. Household contacts were followed up for 7-10 days during 3-4 home visits to monitor symptoms. Nose and throat swabs were collected and tested for influenza by reverse-transcription polymerase chain reaction or viral culture. RESULTS: We followed up 384 index patients and their household contacts. Index patients who took oseltamivir within 24 h of symptom onset halved the time to symptom alleviation (adjusted acceleration factor, 0.56; 95% confidence interval [CI], 0.42-0.76). Oseltamivir treatment was not associated with statistically significant reduction in the duration of viral shedding. Household contacts of index patients who had taken oseltamivir within 24 h of onset had a nonstatistically significant lower risk of developing laboratory-confirmed infection (adjusted odds ratio, 0.54; 95% CI, 0.11-2.57) and a marginally statistically significant lower risk of clinical illness (adjusted odds ratio, 0.52; 95% CI, 0.25-1.08) compared with contacts of index patients who did not take oseltamivir. CONCLUSIONS: Oseltamivir treatment is effective in reducing the duration of symptoms, but evidence of household reduction in transmission of influenza virus was inconclusive.
BACKGROUND: Large clinical trials have demonstrated the therapeutic efficacy of oseltamivir against influenza. We assessed the indirect effectiveness of oseltamivir in reducing secondary household transmission in an incident cohort of influenza index patients and their household members. METHODS: We recruited index outpatients whose rapid test results were positive for influenza from February through September 2007 and January through September 2008. Household contacts were followed up for 7-10 days during 3-4 home visits to monitor symptoms. Nose and throat swabs were collected and tested for influenza by reverse-transcription polymerase chain reaction or viral culture. RESULTS: We followed up 384 index patients and their household contacts. Index patients who took oseltamivir within 24 h of symptom onset halved the time to symptom alleviation (adjusted acceleration factor, 0.56; 95% confidence interval [CI], 0.42-0.76). Oseltamivir treatment was not associated with statistically significant reduction in the duration of viral shedding. Household contacts of index patients who had taken oseltamivir within 24 h of onset had a nonstatistically significant lower risk of developing laboratory-confirmed infection (adjusted odds ratio, 0.54; 95% CI, 0.11-2.57) and a marginally statistically significant lower risk of clinical illness (adjusted odds ratio, 0.52; 95% CI, 0.25-1.08) compared with contacts of index patients who did not take oseltamivir. CONCLUSIONS:Oseltamivir treatment is effective in reducing the duration of symptoms, but evidence of household reduction in transmission of influenza virus was inconclusive.
Authors: Neil M Ferguson; Derek A T Cummings; Simon Cauchemez; Christophe Fraser; Steven Riley; Aronrag Meeyai; Sopon Iamsirithaworn; Donald S Burke Journal: Nature Date: 2005-08-03 Impact factor: 49.962
Authors: M Elizabeth Halloran; Frederick G Hayden; Yang Yang; Ira M Longini; Arnold S Monto Journal: Am J Epidemiol Date: 2006-11-06 Impact factor: 4.897
Authors: R Welliver; A S Monto; O Carewicz; E Schatteman; M Hassman; J Hedrick; H C Jackson; L Huson; P Ward; J S Oxford Journal: JAMA Date: 2001-02-14 Impact factor: 56.272
Authors: Benjamin J Cowling; Matthew P Muller; Irene O L Wong; Lai-Ming Ho; Marie Louie; Allison McGeer; Gabriel M Leung Journal: Epidemiology Date: 2007-03 Impact factor: 4.822
Authors: Laura G Greer; Richard D Leff; Vanessa Laibl Rogers; Scott W Roberts; George H McCracken; George D Wendel; Jeanne S Sheffield Journal: Am J Obstet Gynecol Date: 2011-03-09 Impact factor: 8.661
Authors: Timothy M Uyeki; Henry H Bernstein; John S Bradley; Janet A Englund; Thomas M File; Alicia M Fry; Stefan Gravenstein; Frederick G Hayden; Scott A Harper; Jon Mark Hirshon; Michael G Ison; B Lynn Johnston; Shandra L Knight; Allison McGeer; Laura E Riley; Cameron R Wolfe; Paul E Alexander; Andrew T Pavia Journal: Clin Infect Dis Date: 2019-03-05 Impact factor: 9.079
Authors: W Paul Glezen; Jordana K Schmier; Carrie M Kuehn; Kellie J Ryan; John Oxford Journal: Am J Public Health Date: 2013-01-17 Impact factor: 9.308
Authors: Jonathan Hsu; Nancy Santesso; Reem Mustafa; Jan Brozek; Yao Long Chen; Jessica P Hopkins; Adrienne Cheung; Gayane Hovhannisyan; Liudmila Ivanova; Signe A Flottorp; Ingvil Saeterdal; Arthur D Wong; Jinhui Tian; Timothy M Uyeki; Elie A Akl; Pablo Alonso-Coello; Fiona Smaill; Holger J Schünemann Journal: Ann Intern Med Date: 2012-02-27 Impact factor: 25.391
Authors: Dennis K M Ip; Lincoln L H Lau; Kwok-Hung Chan; Vicky J Fang; Gabriel M Leung; Malik J S Peiris; Benjamin J Cowling Journal: Clin Infect Dis Date: 2015-10-30 Impact factor: 9.079
Authors: J Khoury; M Szwarcwort; Z Kra-Oz; M Saffuri; K Seh; T Yahalomi; E Braun; Z S Azzam; M Paul; A Neuberger Journal: Eur J Clin Microbiol Infect Dis Date: 2017-11-15 Impact factor: 3.267
Authors: Charles R Beck; Rachel Sokal; Nachiappan Arunachalam; Richard Puleston; Anna Cichowska; Anthony Kessel; Maria Zambon; Jonathan S Nguyen-Van-Tam Journal: Influenza Other Respir Viruses Date: 2013-01 Impact factor: 4.380
Authors: Doug H Cheung; Tim K Tsang; Vicky J Fang; Jiajing Xu; Kwok-Hung Chan; Dennis K M Ip; Joseph Sriyal Malik Peiris; Gabriel M Leung; Benjamin J Cowling Journal: J Infect Dis Date: 2015-02-02 Impact factor: 5.226